Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05722015
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-28
First Post:
2023-01-27
Brief Title:
A Study of Subcutaneous SC Pembrolizumab Coformulated With Hyaluronidase MK-3475A vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer NSCLC MK-3475A-D77
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-14
Start Date Type:
ACTUAL
Primary Completion Date:
2024-09-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-05-22
Completion Date Type:
ESTIMATED
First Submit Date:
2023-01-27
First Submit QC Date:
January 27 2023
Study First Post Date:
2023-02-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-26
Last Update Post Date:
2024-02-28
Last Update Post Date Type:
ACTUAL